Literature DB >> 10635407

Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.

A Eisbruch1, L A Dawson, H M Kim, C R Bradford, J E Terrell, D B Chepeha, T N Teknos, Y Anzai, L H Marsh, M K Martel, R K Ten Haken, G T Wolf, J A Ship.   

Abstract

PURPOSE: To develop techniques which facilitate sparing of the major salivary glands while adequately treating the targets in patients requiring comprehensive bilateral neck irradiation (RT). PATIENTS AND METHODS: Conformal and static, multisegmental intensity modulated (IMRT) techniques have been developed. The salivary flow rates before and periodically after RT have been measured selectively from each major salivary gland and the residual flows correlated with glands' dose volume histograms. Subjective xerostomia questionnaires have been developed and validated. The pattern of local-regional recurrences has been examined using CT scans at the time of recurrence, transferring the recurrence volumes to the planning CT scans and regenerating the dose distributions at the recurrence sites.
RESULTS: Target coverage and dose homogeneity in IMRT treatment plans were found to be significantly better than standard RT plans. Significant parotid gland sparing was achieved. The relationships among dose, irradiated volume and saliva flow rates from the parotid glands were characterized by dose and volume thresholds. A mean dose of 26 Gy was found to be the threshold for stimulated saliva. Subjective xerostomia was significantly reduced in patients irradiated with parotid sparing techniques, compared to patients with similar tumors treated with standard RT. The large majority of recurrences occurred inside high-risk targets.
CONCLUSIONS: Tangible gains in salivary gland sparing and target coverage are being achieved and an improvement in some measures of quality of life is suggested by our findings. A mean parotid gland dose of < or = 26 Gy should be a planning objective if significant parotid function preservation is desired. The pattern of recurrence suggests that careful escalation of the dose to targets judged to be at highest risk may improve tumor control.

Entities:  

Mesh:

Year:  1999        PMID: 10635407

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Belg        ISSN: 0001-6497


  17 in total

1.  Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study.

Authors:  Jeremias Hey; Juergen Setz; Reinhard Gerlach; Martin Janich; Guido Hildebrandt; Dirk Vordermark; Christian R Gernhardt; Thomas Kuhnt
Journal:  Radiat Oncol       Date:  2011-09-27       Impact factor: 3.481

Review 2.  Intensity-modulated radiotherapy: is xerostomia still prevalent?

Authors:  Mark S Chambers; Adam S Garden; David Rosenthal; Anesa Ahamad; David L Schwartz; Angel I Blanco; K S Clifford Chao; William H Morrison; K Kian Ang; Randal S Weber
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

3.  Impact of Neck Disability on Health-Related Quality of Life among Head and Neck Cancer Survivors.

Authors:  Marci L Nilsen; Lingyun Lyu; Michael A Belsky; Leila J Mady; Dan P Zandberg; David A Clump; Heath D Skinner; Shyamal Das Peddada; Susan George; Jonas T Johnson
Journal:  Otolaryngol Head Neck Surg       Date:  2019-10-15       Impact factor: 3.497

4.  Changing the perspective: current trends in the assessment of functional outcome in patients with head and neck cancer.

Authors:  Uta Tschiesner
Journal:  Curr Oncol Rep       Date:  2011-04       Impact factor: 5.075

5.  Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.

Authors:  Mona Kamal; David I Rosenthal; Stefania Volpe; Ryan P Goepfert; Adam S Garden; Katherine A Hutcheson; Karine A Al Feghali; Mohamed Ahmed Mohamed Meheissen; Salman A Eraj; Amy E Dursteler; Bowman Williams; Joshua B Smith; Jeremy M Aymard; Joel Berends; Aubrey L White; Steven J Frank; William H Morrison; Richard Cardoso; Mark S Chambers; Erich M Sturgis; Tito R Mendoza; Charles Lu; Abdallah S R Mohamed; Clifton D Fuller; G Brandon Gunn
Journal:  Radiother Oncol       Date:  2017-12-08       Impact factor: 6.280

6.  Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.

Authors:  Paul B Romesser; Oren Cahlon; Eli Scher; Ying Zhou; Sean L Berry; Alisa Rybkin; Kevin M Sine; Shikui Tang; Eric J Sherman; Richard Wong; Nancy Y Lee
Journal:  Radiother Oncol       Date:  2016-02-08       Impact factor: 6.280

7.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

8.  Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.

Authors:  Nancy Y Lee; James G Mechalakos; Sadek Nehmeh; Zhixiong Lin; Olivia D Squire; Shangde Cai; Kelvin Chan; Pasquale B Zanzonico; Carlo Greco; Clifton C Ling; John L Humm; Heiko Schöder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-14       Impact factor: 7.038

9.  The Long-Term Recovery of Parotid Glands in Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiotherapy.

Authors:  Shun Tasaka; Keiichi Jingu; Noriyoshi Takahashi; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Kazuya Takeda; Yu Suzuki; Noriyuki Kadoya
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

10.  Monte Carlo dose verification of prostate patients treated with simultaneous integrated boost intensity modulated radiation therapy.

Authors:  Nesrin Dogan; Ivaylo Mihaylov; Yan Wu; Paul J Keall; Jeffrey V Siebers; Michael P Hagan
Journal:  Radiat Oncol       Date:  2009-06-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.